Related content

Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent

By Markman M.   Kennedy A.   Sutton G.   Hurteau J.   Webster K.   Peterson G.   Kulp B.   Belinson J.  

Gynecologic Oncology, Vol. 70, Iss. 2, 1998-08 ,pp. : 272-274

Elsevier

Access to resources Recommend Favorite

Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis

By Lima Marcos   Ferreira Francisco   Macedo Francisco   Castro Brito Gerly   Ribeiro Ronaldo  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 643-650

Springer Publishing Company

Access to resources Recommend Favorite

Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: Results of a single center in Central Anatolia

By Altinbas Mustafa   Er Ozlem   Ozkan Metin   Coskun Hasan   Gulmez Inci   Ekici Eyup   Kaplan Bunyamin   Eser Bulent   Ozesmi Mustafa  

Medical Oncology, Vol. 21, Iss. 4, 2004-12 ,pp. : 359-366

Humana Press, Inc

Access to resources Recommend Favorite

Ifosfamide/Mesna as Salvage Therapy in Platinum Pretreated Ovarian Cancer Patients—Long-Term Results of a Phase II Study

By Baur Martina   Fazeny-Doerner B.   Hudec M.   Sevelda P.   Salzer H.   Dittrich Christian  

Cancer Investigation, Vol. 24, Iss. 1, 2006-03 ,pp. : 22-27

Informa Healthcare

Access to resources Recommend Favorite

A Phase II Gynecologic Oncology Group Trial of Ifosfamide and Mesna in Advanced or Recurrent Adenocarcinoma of the Endometrium

By Sutton G.P.   Blessing J.A.   deMars L.R.   Moore D.   Burke T.W.   Grendys E.C.  

Gynecologic Oncology, Vol. 63, Iss. 1, 1996-10 ,pp. : 25-27

Academic Press

Access to resources Recommend Favorite